Bill Harriman is Senior Vice President of Antibody Discovery at OmniAb. Dr. Harriman has more than 25 years of biopharma industry experience in the development of innovative antibody-focused technology and project management. Dr. Harriman joined the OmniAb team in 2017 following Ligand Pharmaceuticals’ acquisition of Crystal Bioscience, where he was co-Founder and Chief Scientific Officer, contributing key technology to enable the development of the OmniChicken® platform, and overseeing its implementation in corporate partnerships. Prior to Crystal, Dr. Harriman was an R&D Director at Trellis Bioscience, where he managed antibody discovery projects and was co-inventor of the company’s CellSpot technology platform. Dr. Harriman has also held positions at Abgenix and Roche Diagnostics and is a listed inventor on more than 30 issued or pending patents in the antibody field. Dr. Harriman received his PhD in Immunology from the University of California San Francisco and MBA from the University of California Berkeley.
